Norfloxacin, a new quinoline derivative, was studied in vitro, and determinations of agar dilution minimal inhibitory concentrations (MICs) 
Norfloxacin is a newly developed antibacterial agent that is chemically related to nalidixic acid and cinoxacin. Norfloxacin has been demonstrated in vitro to be extremely active against Enterobacteriaceae, with minimal inhibitory concentrations (MICs) for Escherichia coli, Klebsiella spp., and Proteus spp. normally below 1 ,ug/ml (2) (3) (4) (6) (7) (8) . In addition, norfloxacin seems to include in its spectrum species which are resistant to nalidixic acid, e.g., Pseudomonas spp. and enterococci (2, 4, 8) . The present investigation was undertaken to study the in vitro activity of norfloxacin against gram-positive and gram-negative aerobic bacteria and to evaluate the effect of the technique used for MIC determinations on the susceptibility of these species to norfloxacin, nalidixic acid, and cinox- or lower MICs were obtained with nalidixic acid for most of the strains, and only two strains had broth MICs of more than twice the agar MICs ( Table 2 ). The broth MIC of norfloxacin was four times higher than the agar MIC for three strains and eight times higher for four strains. The broth MIC of cinoxacin was 32 times higher for four strains, 8 times higher for one strain, and 4 times higher for three strains.
A 1,000-fold increase of the inoculum in broth dilution MIC determinations resulted in 8-or 16-fold increases of the MIC for 17 of the strains with nalidixic acid. Such increases were seen for seven of the strains with norfloxacin and for only two strains with cinoxacin.
The MBCs were only slightly higher than the MICs when norfloxacin and cinoxacin were tested. With nalidixic acid, only four E. coli strains had MBCs below 64 p.g/ml, and with a majority of the strains, the MBC fell outside the .highest concentration tested (usually 128 ,ug/ml). Cinoxacin seemed slightly more bactericidal than nalidixic acid, with MBCs below 64 xg/ml at the high inoculum for all strains of Proteus mirabilis, Klebsiella spp., and Citrobacter spp. tested.
DISCUSSION
This study demonstrated that norfloxacin is extremely active against gram-negative aerobic pathogens and that it includes in its spectrum important gram-positive species causing urinary tract infections. Compared with nalidixic acid and cinoxacin, norfloxacin was more active against all strains tested with regard to both bacteriostatic and bactericidal activity. The small differences between the MICs and the MBCs of norfloxacin indicate that development of resistance against this drug might be less common than is the case with nalidixic acid. However, comparing our results with those of King et al. (6) and Neu and Labthavikul (7), we demonstrated higher MBCs than MICs for many of the strains tested, whereas only a few strains in the other studies had higher MBCs than MICs. A possible explanation for this discrepancy is that we used a volume of 0.1 ml for the MBC test, whereas the inocula in the previous reports were 0.001 and 0.01 ml, respectively. There is a possibility, although we did not investigate it, that in some cases, the higher MBCs could be due to selection of mutants that are less susceptible to norfloxacin. Norfloxacin also differs from nalidixic acid and cinoxacin in that it includes in-its antibacterial spectrum Pseudomonas aeruginosa and gram-positive pathogens, species which are completely resistant to the two comparative agents (2, 4, 8) .
When the in vitro activity of norfloxacin is related to available documentation of .the pharmacokinetics of the drug in humans, it is obvious that urine concentrations well above the MICs and MBCs of all strains tested in this study will be maintained for at least 12 h after a single oral dose of 100 mg, after which about 15 F.g of norfloxacin per ml in urine was reported in the 12 to 24-h collection period (1) . However, the drug is incompletely absorbed from the gastrointestinal tract, and the serum concentrations are low (1). Therefore, higher doses would be required to guarantee therapeutic concentrations in tissues and tissue fluids in the treatment of a systemic infection, e.g., pyelonephritis. Although low peripheral concentrations are achieved, it has been demonstrated in experimental infections that norfloxacin at concentrations close to the MIC is bactericidal and effectively eliminates E, coli, Klebsiella pneumoniae, and other pathogens from the site of the infection (2, 5; 22nd ICAAC, abstr. no. 682).
Further clinical evaluation of norfloxacin seems worthwhile partly because of its high antibacterial activity, and especially since it offers one of the very few alternatives for oral treatment of infections caused by Pseudomonas aeruginosa, infections which today may require hospitalization only for the purpose of administration of injectible antibiotics, owing to lack of available oral agents.
